The litigation targets the period between February 20 and August 4, 2026, during which Chemours repeatedly reaffirmed its financial outlook. Plaintiffs contend that the company failed to disclose that significant 2025 overselling had left the aftermarket channel overstocked, masking a lack of genuine demand. These claims gained traction after the firm cut its full-year adjusted EBITDA guidance to a range of $775 million to $825 million on August 4, 2026.
In section Releases
Chemours Faces Securities Litigation Following Guidance Cut and Downgrades
Investors in The Chemours Company are facing a December 7, 2026, deadline to serve as lead plaintiffs in a securities class action. The lawsuit alleges the company misled shareholders by overstating aftermarket demand for its Opteon refrigerants, a disclosure failure that triggered a series of sharp analyst downgrades.
Following the guidance revision, the stock price fell by 18.63%, or $3.34 per share, closing at $14.59. Major financial institutions responded by slashing price targets, with UBS, Morgan Stanley, and J.P. Morgan reducing their valuations by as much as 37.9% within nine days. UBS, which downgraded the stock from Buy to Neutral, cited concerns regarding the underlying earnings stability of the Thermal & Specialized Solutions segment, while other analysts pointed to the unexpected contraction in revenue as a material surprise to the market.
Comments (0)
No comments yet. Be the first!